The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 20 percent of revenues in 2014.
Zalviso® receives positive CHMP opinion
Grünenthal’s Zalviso® 15 micrograms sublingual tablets receives positive CHMP opinion in the EU for treatment of acute moderate to severe post-operative pain in adult patients
The Grünenthal Group announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the marketing authorization of sufentanil sublingual tablets for the management of acute moderate to severe post-operative pain in adult patients. The Zalviso® system, in-licensed from AcelRx Pharmaceuticals Inc., is an innovative drug-device combination for use in hospitals offering several safety features for patients. It utilizes the opioid agonist sufentanil formulated in a proprietary sublingual tablet and delivered through an easy to use pre-programmed, non-invasive administration device.
On an annual basis, there are 19 million surgical procedures with associated moderate to severe pain in the European Union. Management of acute post-operative pain remains a key challenge.